ライフサイエンスコーパス: leucyl

1 PMNs stimulated with N-formyl-1-methionyl-1-leucyl-1-phenylalamine (FMLP) or permeabilized PMNs stim

2 tic agents, including N-formyl-1-methionyl-1-leucyl-1-phenylalanine (FMLP).

3 N/OFQ displaced [leucyl-(3)H]N/OFQ binding with pK(i) and slope values of

4 s, we have examined the effects of N/OFQ on [leucyl-(3)H]N/OFQ(1-17)OH ([leucyl-(3)H]N/OFQ) binding i

5 cts of N/OFQ on [leucyl-(3)H]N/OFQ(1-17)OH ([leucyl-(3)H]N/OFQ) binding in the presence and absence o

6 Optimal activity was observed against L-leucyl-7-amido-4-methylcoumarin (k(cat)/K(m) approximate

7 N-[N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl]-agmatine, a cysteine protease inhibitor.

8 peptide surfactant, poly(sodium undecanoyl-l-leucyl-alaninate), poly(l-SULA), is investigated as a ne

9 -[N-[(l-3-trans-carboxyoxirane-2-carbonyl)-l-leucyl]amino]-4-guanidinobutane (E-64), an inhibitor of

10 , which can be unambiguously assigned to the leucyl aminopeptidase (LAP) structural family.

11 Intronless genes encoding a leucyl aminopeptidase (lap) were cloned from Leishmania

12 mpounds on X-Pro dipeptidase (prolidase) and leucyl aminopeptidase are also presented.

13 most restricted substrate specificity of any leucyl aminopeptidase described to date.

14 M17 leucyl aminopeptidases are metal-dependent exopeptidases

15 d 60-kDa proteins that displayed homology to leucyl aminopeptidases from Gram-negative bacteria, plan

16 e found that the evolutionary-related IleRS, leucyl- and valyl-tRNA synthetases (I/L/VRSs), all effic

17 O-QIC {L-threonine,(3R)-N-acetyl-3-hydroxy-L-leucyl-(aR)-a-hydroxybenzenepropanoyl-2,3- idehydro-N-me

18 -succinyl-beta-alanyl-L-isoleucyl-L-alanyl-L-leucyl-Dox (sAIAL-Dox).

19 [N-succinyl-beta-alanyl-L-leucyl-L-alanyl-L-leucyl-Dox (sALAL-Dox)] has been shown to have an improv

20 This proteolytic cleavage generates leucyl-Dox, which is capable of entering cells and gener

21 gen (PSA) to liberate the active cytotoxin L-leucyl-doxorubicin.

22 In the present study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d w

23 primary target of the compound morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl (LHVS), which was

24 with the calpain inhibitor N-[N-(N-acetyl-l-leucyl)-l-leucyl]-l-norleucine (ALLN) restores endoplasm

25 he small molecule inhibitor N-[N-(N-acetyl-L-leucyl)-L-leucyl]-L-norleucine (ALLN).

26 including 6-OHDA and MG-132 (carbobenzoxy-L-leucyl- L-leucyl-L-leucinal), whereas RNA interference (

27 nyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine did not inhibit basal GTPgammaS

28 (Dox), CPI-0004Na [N-succinyl-beta-alanyl-L-leucyl-L-alanyl-L-leucyl-Dox (sALAL-Dox)] has been shown

29 ; (f) L-isoleucyl-L-leucine dipeptide; (g) L-leucyl-L-isoleucine dipeptide.

30 he amino acid L-isoleucine and the peptide L-leucyl-L-isoleucine showed greater efficiency in translo

31 roteasome inhibitor carbobenzoxyl-l-leucyl-l-leucyl-l-leucinal (MG-132) and the anthracycline idarubi

32 Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), a proteasome inhibitor, indu

33 norvalinal (MG-115), carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), or lactacystin induced NF-ka

34 Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132, a proteasome inhibitor, which

35 oteasome inhibitors [carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132), MG115 (carbobenzoxy-L-leucyl-

36 oteolysis inhibitor carbobenzoxy- L-leucyl-L-leucyl-L-leucinal (MG132).

37 me inhibitor MG-132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) prevented decreases in the size of th

38 6-OHDA and MG-132 (carbobenzoxy-L-leucyl- L-leucyl-L-leucinal), whereas RNA interference (RNAi)-medi

39 3-propanediyl)bis[(phenylmethoxy)carbonyl]-l-leucyl-l-leucinamide ketone inhibits formation of N-term

40 estabilized using the lysosomotropic agent L-leucyl-L-leucine methyl ester (Leu-Leu-OMe).

41 e permeabilization by lysosomotropic agent l-leucyl-l-leucine methyl ester that allows cytosolic rele

42 ith the proteasome inhibitor carbobenzoxyl-l-leucyl-l-leucyl-l-leucinal (MG-132) and the anthracyclin

43 Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), a proteasome inhibi

44 leucyl-L-norvalinal (MG-115), carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), or lactacystin indu

45 Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132, a proteasome inhibit

46 ltiple proteasome inhibitors [carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132), MG115 (carbobenzoxy-

47 asomal proteolysis inhibitor carbobenzoxy- L-leucyl-L-leucyl-L-leucinal (MG132).

48 proteasome inhibitor MG-132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) prevented decreases in the s

49 ycosylated TCRalpha is blocked by N-acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) and lactacystin, im

50 inhibitors, the peptide aldehyde N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL) and the highly spec

51 N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL), which reversibly i

52 easome inhibitors lactacystin and N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL).

53 showed that proteasome inhibitors N-acetyl-L-leucyl-L-leucyl-L-norleucinal and lactacystin but not ly

54 ell specificity in the ability of N-acetyl-L-leucyl-L-leucyl-L-norleucine (LLnL) or doxorubicin to au

55 lective proteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal (MG-115), carbobenzoxy-L-le

56 yl-L-leucinal (MG132), MG115 (carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal), and clasto-lactacystin-be

57 d using the fluorescent peptide N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosine-7-amido-4- methylcoum

58 permeable fluorescent substrate N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosine-7-amido-4-methylcouma

59 A), or the protease inhibitor carbobenzoxy-L-leucyl-L-leucyl-leucinal (MG-132).

60 L-leucyl-L-leucyl-norleucinal and N-acetyl-L-leucyl-L-leucyl-methional.

61 bited by the tripeptide aldehydes N-acetyl-L-leucyl-L-leucyl-norleucinal and N-acetyl-L-leucyl-L-leuc

62 d TCRalpha is blocked by N-acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) and lactacystin, implicating

63 rs, the peptide aldehyde N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL) and the highly specific inhi

64 N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL), which reversibly inhibits t

65 hibitors lactacystin and N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL).

66 at proteasome inhibitors N-acetyl-L-leucyl-L-leucyl-L-norleucinal and lactacystin but not lysosome in

67 ficity in the ability of N-acetyl-L-leucyl-L-leucyl-L-norleucine (LLnL) or doxorubicin to augment rAA

68 roteasome inhibitors carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal (MG-115), carbobenzoxy-L-leucyl-L-le

69 inal (MG132), MG115 (carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal), and clasto-lactacystin-beta-lacton

70 tween Ser 195 of chymotrypsin and N-acetyl-L-leucyl-L-phenylalanal (AcLF-CHO) has also been determine

71 esence and absence of N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) (1 muM) stimulation.

72 cells stimulated with N-Formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) and after pretreatment of

73 1gamma2 reconstituted N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-stimulated guanosine 5'-O-

74 ntify the effects of (N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-stimulation on its mechani

75 a healthy donor with N-formyl-L-methionyl-L-leucyl-L-phenylalanine could also cause them to sediment

76 potent inhibitors of N-formyl-l-methionyl-l-leucyl-l-phenylalanine-induced migration of human neutro

77 s of Ser 195 in chymotrypsin with N-acetyl-L-leucyl-L-phenylalanyl trifluoromethyl ketone (AcLF-CF3)

78 agonist, N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine did not

79 he fluorescent peptide N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosine-7-amido-4- methylcoumarin or t

80 fluorescent substrate N-succinyl-L-leucyl-L-leucyl-L-valyl-L-tyrosine-7-amido-4-methylcouma rin, as

81 calpain inhibitor N-[N-(N-acetyl-l-leucyl)-l-leucyl]-l-norleucine (ALLN) restores endoplasmic spreadi

82 olecule inhibitor N-[N-(N-acetyl-L-leucyl)-L-leucyl]-L-norleucine (ALLN).

83 elective calpain inhibitor benzyloxycarbonyl-leucyl-leucinal (5 micromol/L) prevented the up-regulati

84 e protease inhibitor carbobenzoxy-L-leucyl-L-leucyl-leucinal (MG-132).

85 sence of activator peptides, such as benzoyl-leucyl-leucine (Bz-LL), for function.

86 factor (e.g. the dipeptide benzyloxycarbonyl-leucyl-leucine in vitro) to form the active ClpP1P2 tetr

87 specific proteasome inhibitor carbobenzoxy-l-leucyl-leucyl-l-leucinal (MG132).

88 yl-norleucinal (LLN), or the more potent CBZ-leucyl-leucyl-leucinal (MG132) suppressed proteolysis in

89 he presence of lactacystin and carboxybenzyl-leucyl-leucyl-leucinal, two inhibitors for proteasomal p

90 proteasome-specific inhibitors carboxybenzyl-leucyl-leucyl-leucine vinyl sulfone (Z-L3VS) and lactacy

91 The peptide vinyl sulfone, carboxybenzyl-leucyl-leucyl-leucine vinyl sulfone (Z-L3VS) covalently

92 teasome inhibitor studies with carboxybenzyl-leucyl-leucyl-leucine vinyl sulfone suggest an HCMV-asso

93 G132 (a 26S proteasomal inhibitor), N-acetyl-leucyl-leucyl-norleucinal (a calpain inhibitor), z-VAD-f

94 The calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN) has been reported to ha

95 ished by inhibition of calpain with N-acetyl-leucyl-leucyl-norleucinal (ALLN) or Calpeptin.

96 Compared with bortezomib, MG-132, N-acetyl-leucyl-leucyl-norleucinal (ALLN), and lactacystin, salin

97 by the cysteine protease inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN).

98 ehyde inhibitors of the proteasome, N-acetyl-leucyl-leucyl-norleucinal (LLN), or the more potent CBZ-

99 ncubation with calpain inhibitor I (N-acetyl-leucyl-leucyl-norleucinal [aLLN]), an active-site inhibi

100 ed with two proteolytic inhibitors, N-acetyl-leucyl-leucyl-norleucinal and lactacystin, the latter re

101 Calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal blocked FAK cleavage, cell adh

102 hich was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by the serine protease

103 This maturation is inhibited by N-acetyl-leucyl-leucyl-norleucinal but not lactacystin, indicatin

104 he peptide aldehydes (MG132, MG115, N-acetyl-leucyl-leucyl-norleucinal) and lactacystin, inhibited th

105 E-64 or the calpain inhibitor ALLN (N-acetyl-leucyl-leucyl-norleucinal).

106 by the proteasome inhibitors MG132, N-acetyl-leucyl-leucyl-norleucinal, and lactacystin.

107 g apoB to be rapidly degraded by an N-acetyl-leucyl-leucyl-norleucinal-inhibitable process.

108 y abrogated by proteasome inhibitor N-acetyl-leucyl-leucyl-norleucinal.

109 uine (100 microM), but resistant to N-acetyl-leucyl-leucyl-norleucinal.

110 d HepG2 cells with brefeldin A plus N-acetyl-leucyl-leucyl-norleucinal.

111 teasome inhibitors, lactacystin and N-acetyl-leucyl-leucyl-norlucinal, caused a rapid and near-comple

112 lymphoblasts in culture to benzyloxycarbonyl-leucyl-leucyl-phenylalaninal (Z-LLF-CHO), a cell-permeab

113 oteasome inhibition with either carbobenzoxy-leucyl-leucyl-phenylalaninal or lactacystin led to a los

114 The amino acid editing site for leucyl- (LeuRS) and isoleucyl- (IleRS) tRNA synthetases

115 L-leucyl-norleucinal and N-acetyl-L-leucyl-L-leucyl-methional.

116 yl-1-oxo-2-[(1-oxopropyl)amino]pentyl]oxy]-L-leucyl-N,O-dimethyl-,(7-->1)-lac tone (9CI)}, a novel in

117 nd kappa-receptors were labelled with [(3)H] leucyl-nociceptin (0.4 nM), [(3)H] DAMGO (4 nM), [(3)H]

118 An approximately 50% decrease in [(3)H] leucyl-nociceptin binding was seen in heterozygous ORL1

119 the tripeptide aldehydes N-acetyl-L-leucyl-L-leucyl-norleucinal and N-acetyl-L-leucyl-L-leucyl-methio

120 t a 60-min chase in the presence of N-acetyl-leucyl-norleucinal, more than 90% of microsomes were iso

121 iols of the general structure N-mercaptoacyl-leucyl-p-nitroanilide (1a-c) were synthesized and found

122 nalogue, (S)-2-O-(H-phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide (PCLNA), have been determined.

123 cterial chemotactic peptide formyl-methionyl-leucyl-phenylalamine (fMLF), is activated by peptide dom

124 s significantly increased N-formyl-methionyl-leucyl phenylalanine (fMLF)-stimulated superoxide releas

125 Formyl methionyl leucyl phenylalanine (fMLP) stimulates neutrophils to ad

126 ly 10-fold in response to N-formyl methionyl leucyl phenylalanine (fMLP).

127 ses upon stimulation with N-formyl methionyl leucyl phenylalanine and CC chemokine ligand (CCL) 3 (ne

128 ty in cells stimulated with formyl-methionyl-leucyl phenylalanine plus dihydrocytochalasin B.

129 Mbeta2 integrin following N-formyl-methionyl-leucyl phenylalanine stimulation.

130 eness upon stimulation with formyl-methionyl-leucyl phenylalanine was found to identify sputum eosino

131 y the chemoattractant fMLF (formyl methionyl leucyl phenylalanine) was observed by RICM (reflection i

132 , on FPR1 activation with N-formyl-methionyl-leucyl phenylalanine, WDR26 dissociates from FPR1, resul

133 surface of unactivated and formyl methionyl leucyl phenylalanine-activated PMN as determined by indi

134 and after stimulation with formyl-methionyl-leucyl-phenylalanine (100 nM).

135 non-fluorescent peptide ligand CHO-methionyl-leucyl-phenylalanine (CHO-MLF).

136 the plasma membrane upon N-formyl-methionyl-leucyl-phenylalanine (fMLF) stimulation and colocalizes

137 licited by phorbol ester or formyl-methionyl-leucyl-phenylalanine (fMLF) was unaffected.

138 nd ex vivo perfusion with n-formyl-methionyl-leucyl-phenylalanine (fMLP) (10(-)(7) M).

139 PMN chemotactic responses to formylmethionyl-leucyl-phenylalanine (fMLP) and IL-8 were dose-dependent

140 neutrophils, which binds to formyl-methionyl-leucyl-phenylalanine (fMLP) and plays a role in neutroph

141 and elastase) exposed to N-formyl-methionyl-leucyl-phenylalanine (fMLP) and/or multivalent immune co

142 state 13-alpha-acetate or N-formyl methionyl-leucyl-phenylalanine (fMLP) for stimulus.

143 cells were exposed to an N-formyl-methionyl-leucyl-phenylalanine (FMLP) gradient whose source was pe

144 chemoattractant signal of N-formyl-methionyl-leucyl-phenylalanine (FMLP) in the absence of a spatial

145 his paradigm, we injected N-formyl-methionyl-leucyl-phenylalanine (FMLP) intradermally in guinea pigs

146 e primary chemoattractant N--formylmethionyl-leucyl-phenylalanine (fMLP) is mediated by leukotriene B

147 Microinjection of formyl-methionyl-leucyl-phenylalanine (fMLP) or macrophage inflammatory p

148 n secondary activation by N-formyl-methionyl-leucyl-phenylalanine (FMLP) or phorbol myristate acetate

149 ed human neutrophils with N-formyl-methionyl-leucyl-phenylalanine (fMLP) results in biphasic activati

150 The chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP) stimulated p38-MAPK-dependen

151 followed by treatment with formyl-methionyl-leucyl-phenylalanine (fMLP) stimulates cells in a physio

152 Formyl-methionyl-leucyl-phenylalanine (FMLP) stimulation (10(-7) M) resul

153 e assessed in response to N-formyl-methionyl-leucyl-phenylalanine (fMLP) stimulation.

154 rom cells with or without N-formylmethionine leucyl-phenylalanine (fMLP) stimulation.

155 lation of PMNs with 1 muM N-formyl-methionyl-leucyl-phenylalanine (fMLP) triggered earlier and more s

156 ing N-formylated peptide (N-formyl-methionyl-leucyl-phenylalanine (fMLP)), platelet activating factor

157 coincubated with 0.5 microM formyl-methionyl-leucyl-phenylalanine (fMLP), 1.3 microM 22:6OOH, or 5.0

158 lls permits absorption of N-formyl-methionyl-leucyl-phenylalanine (fMLP), as occurs in hPepT1 express

159 ) and then activated with N-formyl-methionyl-leucyl-phenylalanine (FMLP), C(2)-ceramide (10 microM) c

160 to the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (FMLP), colony stimulating factor-1

161 neutrophils were exposed to formyl-methionyl-leucyl-phenylalanine (fMLP), PKCbetaII was rapidly phosp

162 actic bacterial peptide, N-formyl- methionyl-leucyl-phenylalanine (fMLP), was able to specifically at

163 CNS, and also reduces the N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced neutrophil respirato

164 examine the mechanism of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-mediated formation of CysLT.

165 The kinetics of N-formylmethionyl-leucyl-phenylalanine (fMLP)-mediated neutrophil migratio

166 ion of FPRwt reconstituted N-formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated extracellular sig

167 Our results show that formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated respiratory burst

168 polysaccharide (LPS)- and N-formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated U937 adhesion to

169 d their chemotaxis toward N-formyl-methionyl-leucyl-phenylalanine (FMLP).

170 bacterial chemoattractant, formyl-methionyl-leucyl-phenylalanine (fMLP).

171 ted upon stimulation with N-formyl-methionyl-leucyl-phenylalanine (fMLP).

172 with LPS, RPMI alone, and N formyl-methionyl-leucyl-phenylalanine (FMLP).

173 lammatory stimuli such as N-formyl-methionyl-leucyl-phenylalanine (fMLP).

174 multaneously treated with N-formyl-methionyl-leucyl-phenylalanine and IgE plus polyvalent antigen.

175 ogically relevant agents, N-formyl-methionyl-leucyl-phenylalanine and leukotriene B4, by approximatel

176 CAM-1, and stimulation with formyl-methionyl-leucyl-phenylalanine boosted capture efficiency through

177 ammatory process induced by formyl-methionyl-leucyl-phenylalanine exposure.

178 atelet-activating factor or formyl-methionyl-leucyl-phenylalanine induced beta(2)-integrin-dependent

179 of these compounds inhibit N-formylmethionyl-leucyl-phenylalanine induced spreading of human neutroph

180 ine before stimulation with formyl methionyl-leucyl-phenylalanine inhibited A3 receptor expression an

181 cells were stimulated by N-formyl-methionyl-leucyl-phenylalanine or opsonized zymosan.

182 without the high-affinity N-formylmethionyl-leucyl-phenylalanine receptor antagonist N-tert-butoxyca

183 were assayed in vitro for N-formyl-methionyl-leucyl-phenylalanine receptor binding and superoxide pro

184 mannose receptor, and the N-formyl-methionyl-leucyl-phenylalanine receptor) did not have demonstrated

185 d doubling of the number of formyl-methionyl-leucyl-phenylalanine receptors on the cells.

186 generation before and after formyl-methionyl-leucyl-phenylalanine stimulation was significantly reduc

187 e-colony-stimulating factor/formyl-methionyl-leucyl-phenylalanine stimuli, which can induce eicosanoi

188 ha (TNF-alpha) as well as N-formyl-methionyl-leucyl-phenylalanine treatment leads to increased phosph

189 retains coupling between N-formyl-methionyl-leucyl-phenylalanine tripeptide (FMLP) receptor stimulat

190 e, opsonized zymosan, and N-formyl-methionyl-leucyl-phenylalanine) induce p22(phox) phosphorylation i

191 otype N-formylpeptide fMLF (formyl-methionyl-leucyl-phenylalanine) were both absent in FPR-/- mice.

192 We found that N-formyl-methionyl-leucyl-phenylalanine, an FPR agonist peptide, rapidly in

193 tants interleukin 8, C5a, N-formyl-methionyl-leucyl-phenylalanine, and interleukin 15, adhesion molec

194 ads, Staphylococcus aureus, formyl-methionyl-leucyl-phenylalanine, and zymosan were reduced by approx

195 -produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine, are elevated in high-fat diet-indu

196 neutrophil stimulation with formyl-methionyl-leucyl-phenylalanine, FcgammaR cross-linking, or phospha

197 nse to multiple agonists (N-formyl-methionyl-leucyl-phenylalanine, interleukin-8, and C5a).

198 ntact cells stimulated with formyl-methionyl-leucyl-phenylalanine, intermediate filament assembly is

199 s activated to secrete with formyl-methionyl-leucyl-phenylalanine, intermediate filaments are phospho

200 h configuration with PMA, N-formyl-methionyl-leucyl-phenylalanine, or anti-IgE greatly enhanced proto

201 bol myristate acetate (PMA), formylmethionyl-leucyl-phenylalanine, or Escherichia coli.

202 stimulated with anti-IgE, N-formyl-methionyl-leucyl-phenylalanine, or phorbol 12-myristate 13-acetate

203 hil activation induced by N-formyl-methionyl-leucyl-phenylalanine, phorbol 12-myristate 13-acetate, o

204 od extension induced with N-formyl-methionyl-leucyl-phenylalanine, platelet activating factor, and le

205 on and O(2)(-) responses to formyl-methionyl-leucyl-phenylalanine, reflecting the same cellular pheno

206 by neutrophils, induced by N-formylmethionyl-leucyl-phenylalanine, was strongly inhibited by inhibito

207 also seen in response to N-formyl-methionyl-leucyl-phenylalanine, zymosan-activated serum, or macrop

208 activity and adhesiveness of formylmethionyl-leucyl-phenylalanine- and arachidonic acid-stimulated ne

209 bolish the TNF-alpha- and N-formyl-methionyl-leucyl-phenylalanine-induced activation of acetyltransfe

210 Since the kinetics of formyl-methionyl-leucyl-phenylalanine-induced F-actin response were highl

211 quantitative analysis of N-formyl-methionyl-leucyl-phenylalanine-induced increase in binding of (35)

212 icient in spontaneous and N-formyl-methionyl-leucyl-phenylalanine-induced polarization, 0.5 microM pe

213 phils under conditions of N-formyl-methionyl-leucyl-phenylalanine-mediated cPLA(2)alpha activation.

214 ation, and TNFalpha-primed, formyl-methionyl-leucyl-phenylalanine-stimulated respiratory burst.

215 rachidonate production in N-formyl-methionyl-leucyl-phenylalanine-stimulated U937 cells.

216 onic saline-treatment after formyl methionyl-leucyl-phenylalanine-stimulation augmented A3 receptor e

217 myristate acetate (PMA) and formyl-methionyl-leucyl-phenylalanine.

218 tase after stimulation with formyl-methionyl-leucyl-phenylalanine.

219 er muscle in response to N-formyl- methionyl-leucyl-phenylalanine.

220 ence of the chemoattractant formyl-methionyl-leucyl-phenylalanine.

221 ants, such as the peptide N-formyl-methionyl-leucyl-phenylalanine.

222 ation of Erk and adhesion by formylmethionyl-leucyl-phenylalanineand arachidonic acid.

223 alanyl-lysine-fluorescein and N-formyl-valyl-leucyl-phenylalanyl-lysine-fluorescein to the N-formyl p

224 the fluorescent peptide ligand CHO-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl-lysine-fluorescein

225 Binding kinetics of N-formyl-methionyl-leucyl-phenylalanyl-phenylalanyl-lysine-fluorescein and

226 The leucyl/phenylalanyl-tRNA-protein transferase (L/F-transf

227 tate acetate (PMA)- but not formyl methionyl-leucyl-proline (fMLP)-induced respiratory burst activity

228 BP12 binds the IP3R at residues 1400-1401, a leucyl-prolyl dipeptide epitope that structurally resemb

229 nnel activity via interaction with conserved leucyl-prolyl dipeptides located near the cytoplasmic mo

230 ring to mimic the isobutyl side chain of the leucyl residue of PLG would increase the dopamine recept

231 htly held at a single amino acid position (a leucyl residue) that is buried in a deep pocket lined wi

232 Both the Escherichia coli tyrosyl- and leucyl-RS/tRNA(CUA) pairs were shown to be orthogonal in

233 by downregulating TOR signalling via LARS-1/leucyl-transfer RNA synthase.

234 rom Methanobacterium thermoautotrophicum and leucyl tRNA derived from Halobacterium sp. NRC-1 as an o

235 s caused by decreased protein content of the leucyl tRNA synthetase (LRS) leucine sensor.

236 carboxy-terminal domain (Cterm) of human mt-leucyl tRNA synthetase rescues the pathologic phenotype

237 85% of RNAP III transcription activity using leucyl-tRNA as a template.

238 sma KIC enrichment most accurately predicted leucyl-tRNA enrichment, whereas plasma Leu enrichment wa

239 convenient and reliable surrogate measure of leucyl-tRNA in liver.

240 gnment we have analyzed the Candida albicans leucyl-tRNA synthetase (CaLeuRS) gene (CaCDC60).

241 Human mitochondrial leucyl-tRNA synthetase (hs mt LeuRS) achieves high amino

242 er the overexpression of human mitochondrial leucyl-tRNA synthetase (LARS2) in the cytoplasmic hybrid

243 Escherichia coli leucyl-tRNA synthetase (LeuRS) aminoacylates up to six d

244 Yeast mitochondrial leucyl-tRNA synthetase (LeuRS) binds to the bI4 intron a

245 c and editing activities of Escherichia coli leucyl-tRNA synthetase (LeuRS) demonstrate that the enzy

246 rmatics analyses, we identified two distinct leucyl-tRNA synthetase (LeuRS) genes within all genomes

247 Leucyl-tRNA synthetase (LeuRS) has been identified as a

248 Leucyl-tRNA synthetase (LeuRS) has evolved an editing fu

249 Mitochondrial leucyl-tRNA synthetase (LeuRS) in the yeast Saccharomyce

250 Leucyl-tRNA synthetase (LeuRS) is a class I enzyme, whic

251 Leucyl-tRNA synthetase (LeuRS) is an essential RNA splic

252 In one case, Mycoplasma mobile leucyl-tRNA synthetase (LeuRS) is uniquely missing its e

253 Leucyl-tRNA synthetase (LeuRS) misactivates non-leucine

254 Leucyl-tRNA synthetase (LeuRS) performs dual essential r

255 Leucyl-tRNA synthetase (LeuRS) relies on its editing fun

256 this biocontrol agent targets A. tumefaciens leucyl-tRNA synthetase (LeuRS), an essential enzyme for

257 In leucyl-tRNA synthetase (LeuRS), editing activities that

258 Leucyl-tRNA synthetase (LeuRS), isoleucyl-tRNA synthetas

259 Leucyl-tRNA synthetase (LeuRS), isoleucyl-tRNA synthetas

260 a unique tRNA-dependent mechanism to inhibit leucyl-tRNA synthetase (LeuRS), while the TM84-producer

261 thanogenesis, protein-modifying factors, and leucyl-tRNA synthetase (LeuRS).

262 synthetase (GluRS):tRNA(Glu) and an archaeal leucyl-tRNA synthetase (LeuRS):tRNA(Leu) complex.

263 lpha was found to form a stable complex with leucyl-tRNA synthetase (LeuRS; K(D) = 0.7 microM).

264 ulting from cancer-associated MTOR mutations.Leucyl-tRNA synthetase (LRS) is a leucine sensor of the

265 Leucyl-tRNA synthetase (LRS) is known to function as leu

266 The yeast mitochondrial leucyl-tRNA synthetase (ymLeuRS) performs dual essential

267 Binding of gold-labeled tRNA(Leu) places leucyl-tRNA synthetase and the bifunctional glutamyl-/pr

268 ein, different mutations in Escherichia coli leucyl-tRNA synthetase are combined to unmask the pretra

269 of onychomycosis, inhibits yeast cytoplasmic leucyl-tRNA synthetase by formation of a stable tRNA(Leu

270 he collective motion in Thermus thermophilus leucyl-tRNA synthetase by studying the low frequency nor

271 We present structures of leucyl-tRNA synthetase complexed with analogs of the dis

272 These mutations that altered or abolished leucyl-tRNA synthetase editing were introduced into comp

273 overcome this limitation, we have adapted a leucyl-tRNA synthetase from Methanobacterium thermoautot

274 n identified a mutation in the mitochondrial leucyl-tRNA synthetase gene (lrs-2) that impaired mitoch

275 ell, Bonfils et al. and Han et al. implicate leucyl-tRNA synthetase in this evolving story.

276 A point mutation in CP1 of class I leucyl-tRNA synthetase inactivates deacylase activity an

277 rving cells of leucine or treating them with leucyl-tRNA synthetase inhibitors did not elicit nuclear

278 ted that the transfer of human mitochondrial leucyl-tRNA synthetase into the cybrid cells carrying th

279 cid editing active site for Escherichia coli leucyl-tRNA synthetase resides within the CP1 domain tha

280 tational analysis within yeast mitochondrial leucyl-tRNA synthetase showed that the enzyme has mainta

281 ed conformational changes of T. thermophilus leucyl-tRNA synthetase upon substrate binding and analyz

282 red the refolding of the human mitochondrial leucyl-tRNA synthetase variant H324Q to that of wild typ

283 hreonine-rich region of the Escherichia coli leucyl-tRNA synthetase's CP1 domain that is hypothesized

284 4-Azaleucine, a competitive inhibitor of leucyl-tRNA synthetase, surprisingly triggered the heat

285 be aminoacylated by the human mitochondrial leucyl-tRNA synthetase, we examined the aminoacylation k

286 nate amino acids that can be misactivated by leucyl-tRNA synthetase.

287 he ser-tRNACAG and preventing binding of the leucyl-tRNA synthetase.

288 e mechanochemical motions in T. thermophilus leucyl-tRNA synthetase.

289 d mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase: homozygous c.1565C>A (p.Thr522As

290 erminal domain extension is required by most leucyl-tRNA synthetases (LeuRS) for aminoacylation.

291 cluding a complex between prolyl-(ProRS) and leucyl-tRNA synthetases (LeuRS) in Methanothermobacter t

292 Aminoacylation and editing by leucyl-tRNA synthetases (LeuRS) require migration of the

293 Leucyl-tRNA synthetases (LeuRSs) have an essential role

294 Mycoplasma leucyl-tRNA synthetases (LeuRSs) have been identified in

295 ing pocket within the editing active site of leucyl-tRNA synthetases (LeuRSs).

296 Leucyl-tRNA synthetases have a hydrolytic active site th

297 is activated by methionyl-, isoleucyl-, and leucyl-tRNA synthetases in vivo.

298 editing of mischarged tRNA similar to other leucyl-tRNA synthetases.

299 lytic turnover, thus inhibiting synthesis of leucyl-tRNA(Leu) and consequentially blocking protein sy

300 y a constitutive protein complex composed of leucyl-tRNA-synthetase and folliculin, which regulates m

301 f E. coli TruA in complex with two different leucyl tRNAs in conjunction with functional assays and c